Crescendo Biologics

Crescendo Biologics is a clinical-stage biopharmaceutical company developing multispecific therapeutics based on fully human single-domain antibody fragments engineered for enhanced tumour penetration and selective T cell activation within the tumour microenvironment.

Its lead programme is in Phase 1b clinical trials for metastatic castration-resistant prostate cancer, with a second T cell engager also in the clinic targeting mesothelin-expressing tumours.

The company also holds discovery and development collaborations with Takeda and BioNTech.